Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
91.860
Open
91.520
VWAP
91.63
Vol
954.80K
Mkt Cap
44.25B
Low
90.710
Amount
87.49M
EV/EBITDA(TTM)
18.84
Total Shares
493.24M
EV
49.50B
EV/OCF(TTM)
23.35
P/S(TTM)
4.59
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
2.66B
+6.42%
0.705
-4.78%
2.64B
+7.65%
0.820
+1.19%
2.75B
+9.8%
0.867
+20.45%
Estimates Revision
The market is revising Upward the revenue expectations for Alcon Inc. (ALC) for FY2025, with the revenue forecasts being adjusted by 0.47% over the past three months. During the same period, the stock price has changed by -3.63%.
Revenue Estimates for FY2025
Revise Upward
+0.47%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-3.61%
In Past 3 Month
Stock Price
Go Down
-3.63%
In Past 3 Month
11 Analyst Rating
19.65% Upside
Wall Street analysts forecast ALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALC is 109.91 USD with a low forecast of 89.30 USD and a high forecast of 125.93 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
19.65% Upside
Current: 91.860
Low
89.30
Averages
109.91
High
125.93
19.65% Upside
Current: 91.860
Low
89.30
Averages
109.91
High
125.93
Berenberg
Sam England
Buy
downgrade
2025-07-16
Reason
Berenberg
Sam England
Price Target
2025-07-16
downgrade
Buy
Reason
Berenberg analyst Sam England lowered the firm's price target on Alcon to CHF 90 from CHF 93 and keeps a Buy rating on the shares.
Morgan Stanley
Equal Weight
downgrade
$90 -> $84
2025-07-15
Reason
Morgan Stanley
Price Target
$90 -> $84
2025-07-15
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Alcon to $84 from $90 and keeps an Equal Weight rating on the shares. The firm continues to like the industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
BTIG
Ryan Zimmerman
Buy
maintain
$99 -> $100
2025-07-14
Reason
BTIG
Ryan Zimmerman
Price Target
$99 -> $100
2025-07-14
maintain
Buy
Reason
BTIG analyst Ryan Zimmerman raised the firm's price target on Alcon to $100 from $99 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
Citi
Buy
maintain
$99 -> $101
2025-06-05
Reason
Citi
Price Target
$99 -> $101
2025-06-05
maintain
Buy
Reason
Citi raised the firm's price target on Alcon to CHF 101 from CHF 99 and keeps a Buy rating on the shares.
Kepler Cheuvreux
Hold
to
Buy
upgrade
2025-05-22
Reason
Kepler Cheuvreux
Price Target
2025-05-22
upgrade
Hold
to
Buy
Reason
Kepler Cheuvreux upgraded Alcon to Buy from Hold.
Deutsche Bank
Falko Friedrichs
Buy
to
Hold
downgrade
2025-05-20
Reason
Deutsche Bank
Falko Friedrichs
Price Target
2025-05-20
downgrade
Buy
to
Hold
Reason
Deutsche Bank analyst Falko Friedrichs downgraded Alcon to Hold from Buy with a price target of CHF 80, down from CHF 96.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Alcon AG (ALC.N) is 28.26, compared to its 5-year average forward P/E of 30.42. For a more detailed relative valuation and DCF analysis to assess Alcon AG 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
30.42
Current PE
28.26
Overvalued PE
34.52
Undervalued PE
26.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
18.19
Current EV/EBITDA
17.17
Overvalued EV/EBITDA
20.08
Undervalued EV/EBITDA
16.29
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
4.12
Current PS
4.24
Overvalued PS
4.49
Undervalued PS
3.76
Financials
Annual
Quarterly
FY2025Q1
YoY :
+0.57%
2.47B
Total Revenue
FY2025Q1
YoY :
-7.28%
344.00M
Operating Profit
FY2025Q1
YoY :
+41.13%
350.00M
Net Income after Tax
FY2025Q1
YoY :
+40.00%
0.70
EPS - Diluted
FY2025Q1
YoY :
+23.23%
244.00M
Free Cash Flow
FY2025Q1
YoY :
-9.96%
50.71
Gross Profit Margin - %
FY2025Q1
YoY :
+80.07%
14.64
FCF Margin - %
FY2025Q1
YoY :
+40.24%
14.15
Net Margin - %
FY2025Q1
YoY :
-2.82%
4.83
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 470.5% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
9.7K
Volume
1
6-9
Months
979.5K
Volume
6
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
8
3.0M
Volume
Months
6-9
6
516.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
16.0K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ALC News & Events
Events Timeline
2025-07-07 (ET)
2025-07-07
09:15:36
Alcon to acquire LumiThera, PBM device
2025-05-28 (ET)
2025-05-28
16:43:52
Alcon's Tryptyr approved by FDA for signs and symptoms of Dry Eye Disease
2025-05-13 (ET)
2025-05-13
16:32:41
Alcon cuts FY25 EPS view to $3.05-$3.15 from $3.15-$3.25, consensus $3.24
Sign Up For More Events
Sign Up For More Events
News
3.5
07-22NewsfilterArtificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
8.5
07-12SeekingAlphaKey deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more
8.5
07-07NASDAQ.COMAlcon To Acquire LumiThera And Its Photobiomodulation Device
Sign Up For More News
People Also Watch
ATCOL
Atlas Corp
0
USD
+0.02%
BTG
B2Gold Corp
3.470
USD
-1.42%
ARMN
Aris Mining Corp
7.370
USD
+0.14%
BBU
Brookfield Business Partners LP
25.670
USD
+1.26%
ARBKL
Argo Blockchain PLC
3.020
USD
+0.67%
BHFAL
Brighthouse Financial Inc
18.650
USD
+0.16%
BEP
Brookfield Renewable Partners LP
27.240
USD
-0.58%
ATLCL
Atlanticus Holdings Corp
24.281
USD
-0.28%
BCTX
Briacell Therapeutics Corp
0.799
USD
-1.24%
BKT
Blackrock Income Trust Inc
11.640
USD
+0.17%
FAQ
What is Alcon AG (ALC) stock price today?
The current price of ALC is 91.86 USD — it has decreased -0.04 % in the last trading day.
What is Alcon AG (ALC)'s business?
What is the price predicton of ALC Stock?
What is Alcon AG (ALC)'s revenue for the last quarter?
What is Alcon AG (ALC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Alcon AG (ALC)'s fundamentals?
How many employees does Alcon AG (ALC). have?